Suchergebnisse - "Vališ, Martin"

PubPharm (9)

1

Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis : CLARIFY-MS study 6-month interim analysis

enthalten in: Multiple sclerosis and related disorders | 2022

von Brochet, B. | Hupperts, R. | Langdon, D. | +12

2

Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis : a phase 2b, randomised, double-blind, placebo-controlled trial

enthalten in: The Lancet. Neurology | 2021

von Reich, D. | Arnold, D. | Vermersch, P. | +54

CommentIn: Lancet Neurol. 2021 Sep;20(9):689-691. - PMID 34418385

3

DORADA adherence study : full view into RebiSmart subdomains parameters in multiple sclerosis treatment

enthalten in: Current medical research and opinion | 2021

von Pavelek, Z. | Novotný, M. | Klímová, B. | +4

4

Ofatumumab versus Teriflunomide in Multiple Sclerosis

enthalten in: The New England journal of medicine | 2020

von Hauser, S. | Bar-Or, A. | Cohen, J. | +121

5

An observational study demonstrating the adherence and ease of use of the injector device, RebiSmart®

enthalten in: Expert opinion on drug delivery | 2020

von Vališ, M. | Šarláková, J. | Halúsková, S. | +7

6

Vitamin D, smoking, EBV, and long-term cognitive performance in MS : 11-year follow-up of BENEFIT

enthalten in: Neurology | 2020

von Cortese, M. | Munger, K. | Martínez-Lapiscina, E. | +115

CommentIn: Neurology. 2020 May 5;94(18):771-772. - PMID 32300061

7

Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis

enthalten in: The New England journal of medicine | 2019

von Montalban, X. | Arnold, D. | Weber, M. | +71

CommentIn: Nat Rev Neurol. 2019 Aug;15(8):434. - PMID 31127249

8

Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting

enthalten in: Multiple sclerosis and related disorders | 2018

von Trojano, M. | Butzkueven, H. | Kappos, L. | +108

9

Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA) : a double-blind, randomised, placebo-controlled trial

enthalten in: The Lancet. Neurology | 2015

von Trenkwalder, C. | Chaudhuri, K. | Martinez-Martin, P. | +69

CommentIn: Lancet Neurol. 2015 Dec;14(12):1144-5. - PMID 26494525

1
[1]